Kathleen Madden on Managing AEs From Targeted Therapies for Melanoma
Kathleen M. Madden discusses the management of adverse events (AEs) with BRAF and MEK inhibitors for the treatment of patients with melanoma.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
